Importance Hospitalized patients with COVID-19 are at risk for venous and arterial
thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is unknown. …

… ) as an anticoagulant in COVID-19. We also discuss a subset of non-anticoagulant effects
of heparin that may prove beneficial for the treatment of COVID-19. Finally, we discuss …

… We propose that therapeutic treatment with heparin/LMWH will interfere with several
pathological processes in COVID-19 patients, thereby increasing their survival rate. …

… paper, we reviewed available evidence on heparin treatment in COVID-19 acute illness and
chronic sequalae, focusing on the difference between prophylactic and therapeutic dosage. …

… among patients with coronavirus disease 2019 (Covid-19). We hypothesized that
therapeutic-dose … may improve outcomes in noncritically ill patients who are hospitalized with …

… of LMWH, according to our Hospital Task Force for Therapy in COVID-19 recommendations,
as a single daily subcutaneous injection of enoxaparin: 40 mg/day (4000 IU) in patients with …

… COVID-19; however, there were insufficient data on the optimal use of the therapeutic dose
for low-molecular-weight heparin (… use of different heparin doses in patients with COVID-19. …

… to severe illness in patients with moderate COVID-19. Nevertheless, the trial was … COVID-19
appears to differentiate patients who derive benefit or harm from therapeutic-dose heparin. If …

… the protective effect of the therapeutic dose of LMWH in COVID-19 could be relevant only in
… data on LMWH dose for COVID-19 patients, currently, there are only treatment suggestions …

… with CoronaVirus disease-19 (COVID-19). Accordingly, recent data suggested a beneficial
role of low molecular weight heparin (LMWH), but the optimal dosage of this treatment is …